Binding of beta-d-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: kinetic and crystallographic studiesChrysina, E.D., Kosmopoulou, M.N., Kardakaris, R., Bischler, N., Leonidas, D.D., Kannan, T., Loganathan, D., Oikonomakos, N.G.
(2005) Bioorg.Med.Chem. 13: 765-772
- PubMed: 15653344
- DOI: 10.1016/j.bmc.2004.10.040
- PubMed Abstract:
- Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies
Oikonomakos, N.G.,Kosmopoulou, M.,Zographos, S.E.,Leonidas, D.D.,Chrysina, E.D.,Somsak, L.,Nagy, V.,Praly, J.P.,Docsa, T.,Toth, B.,Gergely, P.
(2002) Eur.J.Biochem. 269: 1684
- Crystallographic studies on alpha and beta-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase
Chrysina, E.D.,Oikonomakos, N.G.,Zographos, S.E.,Kosmopoulou, M.N.,Bischler, N.,Leonidas, D.,Kovacs, L.,Docsa, T.,Gergely, P.,Somsak, L.
(2003) BIOCATAL.BIOTRANSFOR. 21: 233
In an attempt to identify a new lead molecule that would enable the design of inhibitors with enhanced affinity for glycogen phosphorylase (GP), beta-D-glucopyranosyl bismethoxyphosphoramidate (phosphoramidate), a glucosyl phosphate analogue, was tes ...
In an attempt to identify a new lead molecule that would enable the design of inhibitors with enhanced affinity for glycogen phosphorylase (GP), beta-D-glucopyranosyl bismethoxyphosphoramidate (phosphoramidate), a glucosyl phosphate analogue, was tested for inhibition of the enzyme. Kinetic experiments showed that the compound was a weak competitive inhibitor of rabbit muscle GPb (with respect to alpha-D-glucose-1-phosphate (Glc-1-P)) with a Ki value of 5.9 (+/-0.1) mM. In order to elucidate the structural basis of inhibition, we determined the structure of GPb complexed with the phosphoramidate at 1.83 A resolution. The complex structure reveals that the inhibitor binds at the catalytic site and induces significant conformational changes in the vicinity of this site. In particular, the 280s loop (residues 282-287) shifts 0.4-4.3 A (main-chain atoms) to accommodate the phosphoramidate, but these conformational changes do not lead to increased contacts between the inhibitor and the protein that would improve ligand binding.
Institute of Organic and Pharmaceutical Chemistry, The National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece.